CareView Communications (CRVW) 10-Q 14 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 14, 2019
Cover [Abstract]
Entity Registrant Name	CareView Communications Inc
Entity Central Index Key	0001377149
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity File Number	000-54090
Entity Incorporation, State or Country Code	NV
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		139,380,748
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 926,249	$ 1,200,725
Accounts receivable	1,236,850	1,276,992
Other current assets	1,463,085	1,408,426
Total current assets	3,626,184	3,886,143
Property and equipment, net	2,100,775	2,486,666
Other Assets:
Restricted cash		750,000
Intangible assets, net	797,004	746,140
Right to use asset	126,182
Other assets, net	278,408	310,592
Total other assets	1,201,594	1,806,732
Total assets	6,928,553	8,179,541
Current Liabilities:
Accounts payable	349,557	509,298
Notes payable, current portion, net of debt costs of $92,102 and $0	20,271,684	15,513,786
Right to use liability, current portion	134,313
Other current liabilities	3,621,985	1,416,240
Total current liabilities	24,377,539	17,439,324
Long-term Liabilities:
Senior secured convertible notes, net of debt discount and debt costs of $11,196,481 and $14,431,614, respectively	69,638,663	64,374,606
Notes payable, net of debt costs of $0 and $815,062	200,000	4,184,938
Total long-term liabilities	69,838,663	68,559,544
Total liabilities	94,216,202	85,998,868
Stockholders' Deficit:
Preferred stock - par value $0.001; 20,000,000 shares authorized; no shares issued and outstanding
Common stock - par value $0.001; 500,000,000 shares authorized at September 30, 2019 and 300,000,000 shares authorized at December 31, 2018; 139,380,748 shares issued and outstanding at September 30, 2019 and December 31, 2018	139,381	139,381
Additional paid in capital	84,207,552	84,027,883
Accumulated deficit	(171,634,582)	(161,986,591)
Total stockholders' deficit	(87,287,649)	(77,819,327)
Total liabilities and stockholders' deficit	$ 6,928,553	$ 8,179,541

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Notes payable, current debt costs	$ 92,102	$ 0
Senior secured convertible notes, debt discount and debt costs	11,196,481	14,431,614
Notes payable, debt costs	$ 0	$ 815,062
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	20,000,000	20,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	500,000,000	300,000,000
Common stock, issued	139,380,748	139,380,748
Common stock, outstanding	139,380,748	139,380,748

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Revenues, net	$ 1,621,962	$ 1,512,075	$ 4,641,418	$ 4,603,200
Operating expenses:
Network operations	708,349	791,082	2,130,861	2,643,197
General and administration	625,987	769,320	2,095,181	2,468,741
Sales and marketing	94,760	68,458	233,578	298,274
Research and development	410,364	358,864	1,123,884	1,040,444
Depreciation and amortization	178,250	307,069	539,598	1,022,644
Total operating expense	2,017,710	2,294,793	6,123,102	7,473,300
Operating loss	(395,748)	(782,718)	(1,481,684)	(2,870,100)
Other income and (expense)
Interest expense	(2,769,755)	(2,438,627)	(8,173,586)	(9,707,423)
Interest income	118	711	680	2,642
Other income	930	6,199	6,599	18,234
Total other income (expense)	(2,768,707)	(2,431,717)	(8,166,307)	(9,686,547)
Loss before taxes	(3,164,455)	(3,214,435)	(9,647,991)	(12,556,647)
Provision for income taxes
Net loss	$ (3,164,455)	$ (3,214,435)	$ (9,647,991)	$ (12,556,647)
Net loss per share (in dollars per share)	$ (0.02)	$ (0.02)	$ (0.07)	$ (0.09)
Weighted average number of common shares outstanding, basic and diluted (in shares)	139,380,748	139,380,748	139,380,748	139,380,748

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITES
Net loss	$ (9,647,991)	$ (12,556,647)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation	500,546	985,927
Bad debt expense	(7,588)
Amortization of debt discount and debt costs	3,255,935	2,810,889
Amortization of deferred installation costs	67,360	115,088
Amortization of deferred debt issuance and debt financing costs	722,959	225,720
Amortization of intangible assets	39,052	36,717
Interest incurred and paid in kind	1,978,923	4,506,987
Stock based compensation related to options granted	158,866	206,114
Stock based costs related to warrants issued		13,814
Loss on disposal of assets		6,725
Changes in operating assets and liabilities:
Accounts receivable	47,730	(111,788)
Other current assets	(54,658)	(846,750)
Other assets	123,073	12,295
Accounts payable	(159,741)	162,357
Other current liabilities	2,103,099	26,168
Net cash flows used in operating activities	(872,435)	(4,406,384)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(114,654)	(431,222)
Payment for deferred installation costs	(47,472)	(56,401)
Patent, trademark and other intangible asset costs	(89,915)	(101,758)
Net cash flows used in investing activities	(252,041)	(589,381)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from senior secured convertible promissory notes	50,000	3,050,000
Proceeds from promissory notes	200,000
Repayment of notes payable	(150,000)	(150,000)
Net cash flows provided by financing activities	100,000	2,900,000
Decrease in cash	(1,024,476)	(2,095,765)
Cash, cash equivalents and restricted cash, beginning of period	1,950,725	4,566,392
Cash, cash equivalents and restricted cash, end of period	926,249	2,470,627
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	150,000	2,025,000
Cash paid for income taxes
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:
Beneficial conversion features for senior secured convertible notes	$ 20,802	98,363
Revaluation of warrants for modification of loan		$ 13,814

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]	Total
Balance, beginning at Dec. 31, 2017	$ 139,381	$ 83,617,896	$ (145,908,741)	$ (62,151,464)
Balance, beginning (in shares) at Dec. 31, 2017	139,380,748
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Options granted as compensation		89,049		89,049
Beneficial conversion features for senior secured convertible notes		31,784		31,784
Revaluation of Rockwell Holdings I, LLC warrant		13,814		13,814
Net loss			(4,801,061)	(4,801,061)
Balance, ending at Mar. 31, 2018	$ 139,381	83,752,543	(150,709,802)	(66,817,878)
Balance, ending (in shares) at Mar. 31, 2018	139,380,748
Balance, beginning at Dec. 31, 2017	$ 139,381	83,617,896	(145,908,741)	(62,151,464)
Balance, beginning (in shares) at Dec. 31, 2017	139,380,748
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss				(12,556,647)
Balance, ending at Sep. 30, 2018	$ 139,381	83,936,186	(158,465,388)	(74,389,821)
Balance, ending (in shares) at Sep. 30, 2018	139,380,748
Balance, beginning at Mar. 31, 2018	$ 139,381	83,752,543	(150,709,802)	(66,817,878)
Balance, beginning (in shares) at Mar. 31, 2018	139,380,748
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Options granted as compensation		58,649		58,649
Beneficial conversion features for senior secured convertible notes		32,777		32,777
Net loss			(4,541,151)	(4,541,151)
Balance, ending at Jun. 30, 2018	$ 139,381	83,843,969	(155,250,953)	(71,267,603)
Balance, ending (in shares) at Jun. 30, 2018	139,380,748
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Options granted as compensation		58,416		58,416
Beneficial conversion features for senior secured convertible notes		33,801		33,801
Net loss			(3,214,435)	(3,214,435)
Balance, ending at Sep. 30, 2018	$ 139,381	83,936,186	(158,465,388)	(74,389,821)
Balance, ending (in shares) at Sep. 30, 2018	139,380,748
Balance, beginning at Dec. 31, 2018	$ 139,381	84,027,883	(161,986,591)	(77,819,327)
Balance, beginning (in shares) at Dec. 31, 2018	139,380,748
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Options granted as compensation		54,613		54,613
Beneficial conversion features for senior secured convertible notes		6,391		6,391
Net loss			(3,075,763)	(3,075,763)
Balance, ending at Mar. 31, 2019	$ 139,381	84,088,887	(165,062,354)	(80,834,086)
Balance, ending (in shares) at Mar. 31, 2019	139,380,748
Balance, beginning at Dec. 31, 2018	$ 139,381	84,027,883	(161,986,591)	(77,819,327)
Balance, beginning (in shares) at Dec. 31, 2018	139,380,748
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss				(9,647,991)
Balance, ending at Sep. 30, 2019	$ 139,381	84,207,551	(171,571,534)	(87,224,602)
Balance, ending (in shares) at Sep. 30, 2019	139,380,748
Balance, beginning at Mar. 31, 2019	$ 139,381	84,088,887	(165,062,354)	(80,834,086)
Balance, beginning (in shares) at Mar. 31, 2019	139,380,748
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Options granted as compensation		54,320		54,320
Beneficial conversion features for senior secured convertible notes		14,411		14,411
Net loss			(3,407,773)	(3,407,773)
Balance, ending at Jun. 30, 2019	$ 139,381	84,157,618	(168,470,127)	(84,173,128)
Balance, ending (in shares) at Jun. 30, 2019	139,380,748
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Options granted as compensation		49,933		49,933
Net loss			(3,101,407)	(3,164,455)
Balance, ending at Sep. 30, 2019	$ 139,381	$ 84,207,551	$ (171,571,534)	$ (87,224,602)
Balance, ending (in shares) at Sep. 30, 2019	139,380,748

BASIS OF PRESENTATION AND RECEN

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS	NOTE 1 – BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS Interim Financial Statements The accompanying unaudited interim condensed consolidated financial statements of CareView Communications, Inc. (“CareView”, the “Company”, “we”, “us” or “our”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, such financial statements include all adjustments (consisting solely of normal recurring adjustments) necessary for the fair statement of the financial information included herein in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission (the “SEC”). The balance sheet at December 31, 2018 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Results of operations for interim periods are not necessarily indicative of results for the full year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the SEC on March 29, 2019. Revenue Recognition We adopted Accounting Standards Codification (“ASC”) Topic 606 (“ASC 606”) on January 1, 2018 using the full retrospective transition method for recognizing revenue. The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of our services to our customers and will provide financial statement readers with enhanced disclosures. We have employed the practical expedient discussed in ASC 606-10-55-18 related to invoicing as we have the right to consideration from our customers in the amount that corresponds directly with the value to the customer of our performance completed to date and therefore we recognize revenue upon invoicing as further discussed below. Further, for those customers for which we are required to collect sales taxes, we record such sales taxes on a net basis which has no effect on the amount of revenue or expenses recognized as the sales taxes are a flow through to the taxing authority. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation. We offer CareView’s services through a subscription-based contract with each healthcare facility for a standard term of three to five years and have determined we have one performance obligation for our services. We begin to bill monthly subscription fees to the healthcare facility upon official acceptance of the CareView System by the healthcare facility which is when the service is initiated. When services begin, the customer simultaneously receives the use and benefit of that service and we recognize the revenue over time based on the service completed to date as the amount invoiced each month. The contract requires the healthcare facility to pay us the subscription fee monthly. During the term of the contract, we provide continuous monitoring of the CareView System and are required to maintain and service all CareView System equipment. If the healthcare facility requires additional services, the contract is amended accordingly. The company evaluated the disaggregation criteria of ASC 606 and determine that based on the nature, amount, timing and uncertainty of our service revenues, there were no material differences that merited further disaggregation as compared to the total revenue as reported in the accompanying consolidated statements of operations. We defer and capitalize all costs associated with the installation of the CareView System into a healthcare facility until the CareView System is fully operational and accepted by the healthcare facility. Installation costs are specifically identifiable based on the amounts we are charged from third party installers or directly identifiable labor hours incurred for each installation. Upon acceptance, the associated costs are expensed on a straight-line basis over the life of the contract with the healthcare facility. These costs are included in network operations on the accompanying consolidated statements of operations. The table below details the activity in these deferred installation costs during the nine months ended September 30, 2019 and 2018. Nine Months Ended 2019 2018 Balance, beginning of period $ 134,686 $ 215,548 Additions 47,472 56,401 Transfer to expense (67,360 ) (115,088 ) Balance, end of period $ 114,798 $ 156,861 From time to time, we enter into contracts with healthcare facilities wherein full payment of the contractual obligation is paid in advance (“PIA Contracts”). The transaction is recorded as a contract liability in our consolidated financial statements, with revenue recorded and the contract liability reduced as services are provided under the contract. The table below details this activity during the nine months ended September 30, 2019 and 2018. Nine Months Ended 2019 2018 Balance, beginning of period $ 58,559 $ 17,430 Additions 175,370 192,507 Transfer to revenue (131,527 ) (107,535 ) Balance, end of period $ 102,402 $ 102,402 Based on our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. Accordingly, except in the case of PIA Contracts as detailed above, our contracts do not give rise to contract assets or liabilities under ASC 606. Accounts receivable are recorded when the right to consideration becomes unconditional and are reported accordingly on our consolidated financial statements. Accounting Standard Update 2016-02, Leases Under Topic 842, operating lease expense is generally recognized evenly over the term of the lease. The Company has an operating lease primarily consisting of office space with remaining lease terms of 12 months. We adopted Accounting Standard Update (“ASU”) 2016-02, Leases using the cumulative effect transition method for all long-term operating leases as of January 1, 2019. The cumulative impact of the adoption of ASU 2016-02 to the condensed consolidated balance sheet as of January 31, 2019 was as follows: Right to Use Asset $ 236,959 Right to Use Liability-ST $ 166,955 Right to Use Liability-LT $ 83,477 The adoption of ASU 2016-02 did not result in an adjustment to retained earnings. The adoption of ASU-2016-02 represents a change in accounting principle. Earnings Per Share We calculate earnings per share (“EPS”) in accordance with GAAP, which requires the computation and disclosure of two EPS amounts, basic and diluted. Basic EPS is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted EPS is computed based on the weighted average number of common shares outstanding plus all potentially dilutive common shares outstanding during the period under the treasury stock method. Such potential dilutive common shares consist of stock options, warrants and convertible debt. Potential common shares totaling approximately 157,000,000 and 189,000,000 at September 30, 2019 and 2018, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to our reported net loss. CareView Connect CareView Connect is a platform consisting of several products and applications targeted at improving level of care and efficiency. We offer an array of wearable and stationary buttons that allow a resident to summon help either for an emergency or assistance, which can be anything from toileting help to assistance putting on their shoes. We offer a mobile app capable of delivering an alert to the caregiver and allows them document information around that alert. This allows for workflows and reports around the alerts, i.e. how long before the alert was handled, what was the cause of the alert, and if not acknowledged in a timely manner then escalate the alert to another individual or group. This ensures that every alert is responded to timely and is verifiable. The decision as to how the Company will distribute CareView Connect has yet to be determined. Our options include direct sales to the end user, lease/buy purchase plans, or the Company may retain ownership and bill for monitoring services, or a combination of these options. Pending the final distribution decision, the equipment included in the CareView Connect product line is recorded as prepaid equipment on the accompanying condensed consolidated financial statements. Once the distribution decision is made, the CareView Connect equipment will be transferred to inventory or deployable fixed assets as appropriate. Recently Issued and Newly Adopted Accounting Pronouncements Aside from the change noted in Leases NOTE 2

GOING CONCERN, LIQUIDITY AND MA

GOING CONCERN, LIQUIDITY AND MANAGMENT'S PLAN	9 Months Ended
	Sep. 30, 2019
Going Concern Liquidity And Managments Plan
GOING CONCERN, LIQUIDITY AND MANAGMENT'S PLAN	NOTE 2 – GOING CONCERN, LIQUIDITY AND MANAGEMENT’S PLAN Our cash position at September 30, 2019 was approximately $926,000. Accounting standards require management to evaluate our ability to continue as a going concern for a period of one year subsequent to the date of the filing of this Form 10-Q (“evaluation period”). As such, we have evaluated if cash and cash equivalents on hand and cash generated through operating activities would be sufficient to sustain projected operating activities through November 14, 2020. We anticipate that our current resources, along with cash generated from operations, will not be sufficient to meet our cash requirements throughout the evaluation period, including funding anticipated losses and scheduled debt maturities. We expect to seek additional funds from a combination of dilutive and/or nondilutive financings in the future. Because such transactions have not been finalized, receipt of additional funding is not considered probable under current accounting standards. If we do not generate sufficient cash flows from operations and obtain sufficient funds when needed, we expect that we would scale back our operating plan by deferring or limiting some, or all, of our capital spending, reducing our spending on travel, and/or eliminating planned headcount additions, as well as other cost reductions to be determined. Because such contingency plans have not been finalized (the specifics would depend on the situation at the time), such actions also are not considered probable for purposes of current accounting standards. Because, under current accounting standards, neither future cash generated from operating activities, nor management’s contingency plans to mitigate the risk and extend cash resources through the evaluation period, are considered probable, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern. As we continue to incur losses, our transition to profitability is dependent upon achieving a level of revenues adequate to support its cost structure. We may never achieve profitability, and unless and until doing so, we intend to fund future operations through additional dilutive or non-dilutive financings. There can be no assurances, however, that additional funding will be available on terms acceptable to us, if at all.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2019
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	NOTE 3 – STOCKHOLDERS’ EQUITY Common Stock On April 11, 2019 the Board of Directors of the Company approved an amendment (the “Charter Amendment”) to our Articles of Incorporation to increase the number of authorized shares of Common Stock, par value $0.001, from 300,000,000 shares to 500,000,000 shares. Subsequently, on May 14, 2019, the Charter Amendment was approved by written consent of the holders of 72,863,770 shares of our Common Stock, representing approximately 52% of our outstanding shares of Common Stock, in lieu of a special meeting. The Charter Amendment was filed with the Secretary of State of the State of Nevada on, and effective as of, June 26, 2019. Also, on April 11, 2019, the Board of Directors approved an amendment to the Company’s Bylaws to amend Section 8, Action Without a Meeting, to replace the wording of that section in its entirety. Warrants to Purchase Common Stock of the Company We use the Black-Scholes-Merton option pricing model (“Black-Scholes Model”) to determine the fair value of warrants to purchase Common Stock of the Company (“Warrants”). The Black-Scholes Model is an acceptable model in accordance with the GAAP. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the weighted average risk-free interest rate, and the weighted average term of the Warrant. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the Warrants. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the expected life of the award. Our estimated volatility is an average of the historical volatility of our stock prices (and that of peer entities whose stock prices were publicly available) over a period equal to the expected life of the awards. Where appropriate we used the historical volatility of peer entities due to the lack of sufficient historical data of our stock price during 2007-2009. Warrant Activity during the Nine Months Ended September 30, 2019 On May 15, 2019, we issued 250,000 ten-year Warrants (with a fair value of $4,000) at an exercise price of $0.03 per share to a director. Warrant Activity during the Nine Months Ended September 30, 2018 On February 23, 2018, we issued an aggregate of 487,500 ten-year Warrants (with a fair value of $10,237) at an exercise price of $0.05 per share to certain directors and officers and 25,000 ten-year Warrants (with a fair value of $525) at an exercise price of $0.05 per share to an entity. On March 31, 2018, 2,500,000 Warrants issued in connection with a private placement completed in April 2013 expired and the fair value of $11,157 was written off and recorded as expense on the accompanying condensed consolidated financial statements. On July 10, 2018, we entered into the Ninth Amendment to the HealthCor Purchase Agreement (the “Ninth Amendment”) with HealthCor, pursuant to which they agreed to amend the HealthCor Purchase Agreement and the 2011 HealthCor Notes canceling 11,782,859 Warrants associated with the HealthCor Purchase Agreement and the 2011 HealthCor Notes (see NOTE 10 Options to Purchase Common Stock of the Company During the nine months ended September 30, 2019 and 2018, no options to purchase our Common Stock were granted. During the nine months ended September 30, 2019, 938,665 Options expired, and 40,000 Options were canceled. During the nine months ended September 30, 2018, no Options were granted. During the same nine-month period, 686,836 Options expired and 214,997 Options were canceled. A summary of our stock option activity and related information follows: Number of Shares Under Options Weighted Average Exercise Price Weighted Aggregate Intrinsic Value Balance at December 31, 2018 21,700,293 $ 0.27 7.1 $ — Expired (938,665 ) Canceled (40,000 ) Balance at September 30, 2019 20,721,628 $ 0.25 6.5 $ — Vested and Exercisable at September 30, 2019 14,082,298 $ 0.33 5.8 $ — Share-based compensation expense for Options charged to our operating results for the nine months ended September 30, 2019 and 2018 ($158,866 and $206,114, respectively) is based on awards vested. The estimate of forfeitures are to be recorded at the time of grant and revised in subsequent periods if actual forfeitures differ from the estimates. We have not included an adjustment to our stock-based compensation expense based on the nominal amount of the historical forfeiture rate. We do, however, revise our stock-based compensation expense based on actual forfeitures during each reporting period. At September 30, 2019, total unrecognized estimated compensation expense related to non-vested Options granted prior to that date was approximately $107,000, which is expected to be recognized over a weighted-average period of 1 year. No tax benefit was realized due to a continued pattern of operating losses.

OTHER CURRENT ASSETS

OTHER CURRENT ASSETS	9 Months Ended
	Sep. 30, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
OTHER CURRENT ASSETS	NOTE 4 – OTHER CURRENT ASSETS Other current assets consist of the following: September 30, December 31, 2018 Prepaid equipment $ 1,283,309 $ 1,327,156 Oher prepaid expenses 166,246 66,888 Other current assets 13,530 14,382 TOTAL OTHER CURRENT ASSETS $ 1,463,085 $ 1,408,426

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 5 – PROPERTY AND EQUIPMENT Property and equipment consist of the following: September 30, December 31, 2018 Network equipment $ 12,388,147 $ 12,302,328 Office equipment 305,250 293,709 Vehicles 217,004 217,004 Test equipment 192,384 175,603 Furniture 91,341 90,827 Warehouse equipment 9,524 9,524 Leasehold improvements 5,121 5,121 13,208,771 13,094,116 Less: accumulated depreciation (11,107,996 ) (10,607,450 ) TOTAL PROPERTY AND EQUIPMENT $ 2,100,775 $ 2,486,666 Depreciation expense for the nine months ended September 30, 2019 and 2018 was $500,546 and $985,927, respectively.

OTHER ASSETS

OTHER ASSETS	9 Months Ended
	Sep. 30, 2019
Other Assets:
OTHER ASSETS	NOTE 6 – OTHER ASSETS Intangible assets consist of the following: September 30, 2019 Cost Accumulated Amortization Net Patents and trademarks $ 1,022,064 $ 229,448 $ 792,616 Other intangible assets 63,509 59,121 4,388 TOTAL INTANGIBLE ASSETS $ 1,085,573 $ 288,569 $ 797,004 December 31, 2018 Cost Accumulated Amortization Net Patents and trademarks $ 932,149 $ 192,995 $ 739,154 Other intangible assets 63,508 56,522 6,986 TOTAL INTANGIBLE ASSETS $ 995,657 $ 249,517 $ 746,140 Other assets consist of the following: September 30, 2019 Cost Accumulated Amortization Net Deferred installation costs $ 1,857,886 $ 1,743,088 $ 114,798 Prepaid license fee 249,999 132,513 117,486 Security deposit 46,124 — 46,124 TOTAL OTHER ASSETS $ 2,154,009 $ 1,875,601 $ 278,408 Other assets consist of the following: December 31, 2018 Cost Accumulated Amortization Net Deferred installation costs $ 1,810,414 $ 1,675,728 $ 134,686 Prepaid license fee 249,999 120,217 129,782 Security deposit 46,124 — 46,124 TOTAL OTHER ASSETS $ 2,106,537 $ 1,795,945 $ 310,592

OTHER CURRENT LIABILITIES

OTHER CURRENT LIABILITIES	9 Months Ended
	Sep. 30, 2019
Payables and Accruals [Abstract]
OTHER CURRENT LIABILITIES	NOTE 7 – OTHER CURRENT LIABILITIES Other current liabilities consist of the following: September 30, December 31, 2018 Accrued interest $ 2,963,381 $ 750,548 Deferred commission 139,041 117,206 Accrued paid time off 108,999 129,773 Deferred revenue 102,402 58,559 Allowance for system removal 101,100 236,650 Accrued insurance 77,440 — Other accrued liabilities 64,860 31,568 Accrued taxes 64,763 23,156 Accrued rent expense — 68,780 TOTAL OTHER CURRENT LIABILITIES $ 3,621,985 $ 1,416,240

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 8 – INCOME TAXES Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay any significant federal or state income tax for 2019 as a result of the losses recorded during the nine months ended September 30, 2019 and the additional losses expected for the remainder of 2019 and net operating loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all of the benefits of deferred tax assets will not be realized. As of September 30, 2019, we maintained a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period. The Tax Cuts and Jobs Act (the “Act”) was signed into law on December 22, 2017. Among its numerous changes to the Internal Revenue Code, the Act reduces U.S. corporate rates from 35% to 21%. Additionally, the Act limits the use of net operating loss carry backs, however any future net operating losses will instead be carried forward indefinitely. Net operating losses generated from January 1, 2018 are limited to offset 80% of current income, with the remainder of the net operating loss continuing to carry forward indefinitely. Net operating losses incurred before January 1, 2018 are not subject to the 80% limitations and will begin to expire in 2029. Based on an initial assessment of the Act, the Company believes that the most significant impact on the Company’s consolidated financial statements will be limitations in tax deductions on interest expense. Under the Act, interest deductions disallowed from current income will carryforward indefinitely. The Act did not impact management’s valuation allowance position.

AGREEMENT WITH PDL BIOPHARMA, I

AGREEMENT WITH PDL BIOPHARMA, INC.	9 Months Ended
	Sep. 30, 2019
Agreement With Pdl Biopharma Inc.
AGREEMENT WITH PDL BIOPHARMA, INC.	NOTE 9 – AGREEMENT WITH PDL BIOPHARMA, INC. On June 26, 2015, we entered into a Credit Agreement (as subsequently amended) with PDL BioPharma, Inc. (“PDL”), as administrative agent and lender (“the Lender”) (the “PDL Credit Agreement”). Under the PDL Credit Agreement the Lender made available to us up to $40 million in two tranches of $20 million each. Tranche One was funded on October 8, 2015 (the “Tranche One Loan’). Pursuant to the terms of the PDL Credit Agreement and having not met the Tranche Two Milestones by July 26, 2017, the Tranche Two funding was terminated in full. From October 8, 2015 through May 14, 2019, the outstanding borrowings under the Tranche One Loan bore interest at the rate of 13.5% per annum, payable quarterly. On May 15, 2019, pursuant to the terms of the Fifth Amendment to the PDL Credit Agreement (see below for additional details), the interest increased to 15.5% per annum, payable quarterly. Also, on May 15, 2019, pursuant to the terms of the Fourteenth Amendment to the PDL Modification Agreement (see below for additional details), the minimum cash balance requirement of $750,000 was reduced to $0. On June 26, 2015, we issued Warrants to PDL for the purchase of an aggregate of 4,444,445 shares of our Common Stock at an exercise price of $0.45 per share (the “PDL Warrant”). On October 7, 2015, we entered into a First Amendment to the PDL Credit Agreement (the “First Amendment”). The First Amendment modified the conditions precedent to the funding of each tranche, such that, among other things, we no longer need to attain a specified milestone relating to the placement of our products in order for the Lender to fund us the Tranche One Loan. Contemporaneously with the execution of the First Amendment we borrowed the Tranche One Loan and issued to the Lender a term note in the principal amount of $20 million (the “Tranche One Term Note”), payable in accordance with the terms of the PDL Credit Agreement, as amended. On October 7, 2015, we also amended and restated the PDL Warrant changing the exercise price from $0.45 to $0.40 per share (the “Amended PDL Warrant”). We evaluated whether there was an increase in fair value which would require recognition of additional costs. No such increase in fair value was noted and no adjustment to the PDL Warrant valuation was necessary. On December 28, 2017, the Company and PDL Investment Holdings, LLC (as assignee of PDL) (“PDL Investment”) entered into a Binding Forbearance Term Sheet (the “Forbearance Term Sheet”) in order to modify certain provisions of the PDL Credit Agreement to prevent any Events of Default from occurring on December 31, 2017. This Forbearance Term Sheet was the governing document until February 2, 2018, at which time, the Company and PDL Investment entered into a Modification Agreement (the “PDL Modification Agreement”), effective December 28, 2017, with respect to the PDL Credit Agreement which reiterated the terms included in the Forbearance Term Sheet and effective February 2, 2018, entered into certain consents and amendments with respect to other existing agreements. In accordance with GAAP, we accounted for this transaction as a debt modification, wherein consideration given to PDL was recorded as deferred closing costs and all third-party payments were considered an expense and recorded as such on the accompanying condensed consolidated financial statements. Details of the PDL Modification Agreement, as amended, are included in our Form 10-K filed with the SEC on March 29, 2019. Pursuant to the terms of the PDL Modification Agreement, as amended, the first principal payment on the Tranche One Loan due on December 31, 2017 in the amount of $1,666,667, and similar principal payments due on March 31, 2018, June 30, 2018, September 30, 2018, December 31, 2018, March 31, 2019, June 30, 2019, and September 30, 2019 have been delayed and are included in the payment due on November 30, 2019 (see Fifteenth Amendment to the PDL Modification Agreement below for additional details). In accordance with the PDL Credit Agreement, as amended, quarterly interest only payments of $675,000 for each of the first 12 interest payment dates (December 31, 2015 through September 30, 2018) were made timely. Pursuant to the terms of the PDL Modification Agreement, as amended, quarterly interest payments due on December 31, 2018, March 31, 2019, June 30, 2019, and September 30, 2019 have been delayed and are also included in the payment due on September 30, 2019 (see Fifteenth Amendment to the PDL Modification Agreement below for additional details). The obligations under the PDL Credit Agreement, as modified, are secured by a pledge of substantially all of the assets of the Company and certain of its domestic subsidiaries. We executed a Subordination and Intercreditor Agreement (the “Subordination and Intercreditor Agreement”), with the Lender, HealthCor, the 2015 Investors, the February 2018 Investors, the July 2018 Investors, and the 2019 Investor (as defined in NOTE 10 The PDL Credit Agreement, as modified, contains customary affirmative covenants for transactions of this type and other affirmative covenants agreed to by the Company and the Lender, including, among others, the provision of annual and quarterly reports, maintenance of property, insurance, compliance with laws and contractual obligations and payment of taxes. The PDL Credit Agreement, as modified, contains customary negative covenants for transactions of this type and other negative covenants agreed to by the Company and the Lender, including, among others, restrictions on the incurrence of indebtedness, the granting of liens, making restricted payments and investments, entering into affiliate transactions and transferring assets. The PDL Credit Agreement, as modified, calls for a reduction of our operating expenses compared to such expense incurred in October 2017 by at least (i) $113,000 for January 2018, (ii) $148,000 for February 2018 and (iii) $167,000 for each other month for the duration of the Modification Period (see Fourteenth Amendment to the PDL Modification Agreement below for additional details). We are in compliance with this covenant as of the date of this filing. The PDL Credit Agreement, as modified, also provides for a number of customary events of default, including payment, bankruptcy, covenant, representation and warranty and judgment defaults. In addition, contemporaneously with the execution of the PDL Credit Agreement the Company and the Lender executed (i) a Registration Rights Agreement (as amended in the PDL Modification Agreement as discussed above) pursuant to which we agreed to provide the Lender with certain registration rights with respect to the shares of Common Stock issuable upon exercise of the PDL Warrant, (ii) a Guarantee and Collateral Agreement pursuant to which certain of our subsidiaries guaranteed the performance of our obligations under the PDL Credit Agreement, as modified, and granted the Lender a security interest in such subsidiaries’ tangible and intangible assets securing our performance of the same, and (iii) a Patent Security Agreement and a Trademark Security Agreement pursuant to which we granted the Lender a security interest in a certain subsidiary’s tangible and intangible assets securing the performance of our obligations under the PDL Credit Agreement, as modified. On January 31, 2019, February 28, 2019, March 29, 2019 and April 29, 2019, the Company and Lender entered into the Tenth, Eleventh, Twelfth, and Thirteenth Amendments to the PDL Modification Agreement, as previously amended, respectively, pursuant to which the parties agreed to amend the PDL Modification Agreement to provide that (A) the dates on which the Lender may elect, in the Lender’s sole discretion, to terminate the Modification Period would be July 31, 2018 and, pursuant to the Thirteenth Amendment to the PDL Modification Agreement, May 15, 2019 (rather than January 31, February 28, March 31, and April 30, respectively) (with each such date permitted to be extended by the Lender in its sole discretion); (B) the Company could satisfy its obligations under the PDL Modification Agreement, as amended, to obtain financing by obtaining (a) at least $2,050,000 in net cash proceeds from the issuance of Capital Stock (other than Disqualified Capital Stock) or Debt on or prior to February 23, 2018 and (b) an additional (i) $750,000 in net cash proceeds from the issuance of Capital Stock (other than Disqualified Capital Stock) or Debt on or prior to July 13, 2018 and (ii) $750,000 in net cash proceeds from the issuance of Capital Stock (other than Disqualified Capital Stock) or Debt on or prior to May 15, 2019 (rather than January 31, February 28, March 31, and April 30, respectively) (resulting in aggregate net cash proceeds of at least $3,550,000); and (C) the Company’s quarterly interest payments that would otherwise have been due to Lender on December 31, 2018 and March 31, 2019 would be deferred until May 15, 2019 (the end of the extended Modification Period) and that such deferral would be a Covered Event. On April 9, 2019, the Company, PDL Investment entered into a Fourth Amendment to PDL Credit Agreement (the “Fourth Amendment to the PDL Credit Agreement”), wherein the Company executed an Amended and Restated Tranche One Term Note in the principal amount of $20,000,000 to PDL Investments (the “Amended Tranche One Loan”), pursuant to which the parties agreed, among other things, to amend the note from registered to unregistered form. On May 15, 2019, the Company, the Lender, Steven G. Johnson (our Chief Executive Officer, President, Secretary and Treasurer), individually, and Dr. James R. Higgins (a member of our board of directors), individually (Mr. Johnson and Dr. Higgins, collectively, the “Tranche Three Lenders”) entered into a Fifth Amendment to the PDL Credit Agreement (the “Fifth PDL Credit Agreement Amendment”), pursuant to which the parties agreed to amend the PDL Credit Agreement to, among other things, (i) provide for a new tranche of term loan in the aggregate principal amount of $200,000, from the Tranche Three Lenders, with a maturity date of October 7, 2020 and bearing interest at the rate of 15.5% per annum, payable quarterly in arrears (subject to the terms of the PDL Modification Agreement, as amended) (the “Tranche Three Loan”); (ii) increase the interest rate for outstanding borrowings under the Amended Tranche One Loan from 13.5% per annum to 15.5% per annum, payable quarterly in arrears (subject to the terms of the PDL Modification Agreement, as amended), effective May 15, 2019,; and (iii) provide for the issuance of the Twelfth Amendment Note, pursuant to the terms of the Twelfth Amendment to the HealthCor Agreement (see Note 10 for details). Under the accounting standards, we determined that the restructuring of the Tranche One Loan resulted in a troubled debt restructuring. As the future cash flows were greater than the carrying amount of the debt at the date of the amendment, we accounted for the change prospectively using the new effective interest rate. On May 15, 2019 the Company and the Lender entered into the Fourteenth Amendment to the PDL Modification Agreement (the “Fourteenth Amendment to the PDL Modification Agreement”), pursuant to which, in connection with the Twelfth Amendment to the HealthCor Purchase Agreement (see NOTE 10 for further details) and the Fifth Amendment to the PDL Credit Agreement, the parties agreed to amend the PDL Modification Agreement, as previously amended, to provide that (A) the dates on which the Lender may elect, in the Lender’s sole discretion, to terminate the Modification Period would be July 31, 2018 and September 30, 2019 (with each such date permitted to be extended by the Lender in its sole discretion); (B) the Borrower could satisfy its obligations under the PDL Modification Agreement, as amended, to obtain financing by obtaining (a) at least $2,050,000 in net cash proceeds from the issuance of Capital Stock (other than Disqualified Capital Stock) or Debt on or prior to February 23, 2018 and (b) an additional (i) $1,000,000 in net cash proceeds from the issuance of Capital Stock (other than Disqualified Capital Stock) or Debt on or prior to July 13, 2018 and (ii) $250,000 in net cash proceeds from the issuance of Capital Stock (other than Disqualified Capital Stock) or Debt on or prior to May 15, 2019 (resulting in aggregate net cash proceeds of at least $3,300,000); (C) the Liquidity required during the Modification Period would be lowered to $0 from $750,000; and (D) the Company’s interest payments that would otherwise be due to Lender on December 31, 2018, March 31, 2019 and June 30, 2019 would be deferred until September 30, 2019 (the end of the extended Modification Period) and that such deferrals would be a Covered Event. On September 30, 2019, the Company, the Borrower, the Subsidiary Guarantor and the Lender entered into a Fifteenth Amendment to Modification Agreement (the “Fifteenth Modification Agreement Amendment”), pursuant to which the parties agreed to amend the Modification Agreement to provide that the dates on which the Lender may elect, in the Lender’s sole discretion, to terminate the Modification Period would be July 31, 2018 and November 30, 2019 (with each such date permitted to be extended by the Lender in its sole discretion); and that the Borrower’s interest payments that would otherwise be due to Lender on December 31, 2018, March 31, 2019, June 30, 2019, and September 30, 2019 would be deferred until November 30, 2019 (the end of the extended Modification Period) and that such deferrals would be a Covered Event. The Company has evaluated the Fifteenth Amendment and as the effective borrowing rate under the restructured agreement is less than the effective borrowing rate on the old agreement, a concession is deemed to have been granted under ASC 470-60-55-10. As a concession has been granted, the agreement is to be accounted for as a troubled debt restructuring by debtors (TDR) under ASC 470-60. Accounting Treatment In connection with the PDL Credit Agreement, as amended, we issued the PDL Warrant to the Lender. The fair value of the PDL Warrant at issuance was $1,257,778, which has been recorded as deferred issuance costs in the accompanying condensed consolidated financial statements. The deferred debt issuance and closing costs associated with the PDL Credit Agreement, as amended, have been presented as contra debt in accordance with the accounting standards. In December 2017, in connection with the PDL Modification Agreement, as amended, the Amended PDL Warrant was again amended (the “Second Amendment to the PDL Warrant’) resulting in an increase in fair value of $44,445, which was recorded as additional deferred debt issuance costs in the accompanying consolidated financial statements. As of September 30, 2019, the Amended PDL Warrant has not been exercised. At September 30, 2019, the outstanding balance of certain debt issuance and closing costs related to the PDL Credit Agreement totaling $92,102 was recorded as deferred closing costs in the accompanying condensed consolidated financial statements. Historically, the deferred closing costs had been presented as other assets, as the costs were incurred prior the first draw down. The costs should have been reclassified as a direct deduction of the debt when the funds were provided. The costs are presented as a direct deduction from the debt as of September 30, 2019, and $815,062 of such costs that were historically presented as other assets have been reclassified as contra debt in the consolidated balance sheet as of December 31, 2018. Management evaluated this classification error on prior period financial statements and concluded the impact was immaterial. Through December 31, 2018, these costs were amortized to interest expense using the straight-line method over the term of the PDL Credit Agreement, as amended. During the nine months ended the Company and Lender entered into six amendments to the PDL Modification Agreement (as detailed above), resulting in restructuring of the PDL Credit Agreement and the accounting treatment of the related costs. Under debt modification under ASC 470-50/troubled debt guidance under ASC 470-60, we determined that the first of the six amendments qualified for modification accounting, while the final five qualified for troubled debt restructuring accounting. As appropriate, we expensed the debt issuance costs paid to third parties, recognized the costs paid to PDL as a deferred debt issuance costs and accounted for the change in the effective interest rate prospectively. For the three- and nine-month periods ended September 30, 2019 $200,712 and $722,959, respectively, was amortized to interest expense. For the three- and nine-month periods ended September 30, 2018 $75,240 and $225,720, respectively, was amortized to interest expense. At September 30, 2019, pursuant to the terms of the PDL Modification Agreement, as amended, $2,858,611 was recorded as accrued interest on the accompanying condensed consolidated financial statements. The Tranche Three Warrant issued with the Fifth PDL Credit Agreement Amendment did not contain features requiring liability accounting and were recorded at fair value on the date of issuance with the offsetting credit recorded in equity. The value allocated to the Tranche Three Loan Warrant was $3,704 and was recorded as interest expense at June 30, 2019. At September 30, 2019, total PDL debt outstanding was of $20,000,000 presented as current on the accompanying consolidated financial statements and net of deferred issuance costs of $92,000.

AGREEMENT WITH HEALTHCOR

AGREEMENT WITH HEALTHCOR	9 Months Ended
	Sep. 30, 2019
Agreement With Healthcor
AGREEMENT WITH HEALTHCOR	NOTE 10 – AGREEMENT WITH HEALTHCOR On April 21, 2011, we entered into a Note and Warrant Purchase Agreement (as subsequently amended) with HealthCor Partners Fund, LP (“HealthCor Partners”) and HealthCor Hybrid Offshore Master Fund, LP (“HealthCor Hybrid” and, together with HealthCor Partners, “HealthCor”) . Subject to the terms of the Ninth Amendment as discussed below, HealthCor’s ability to convert any portion of the outstanding and unpaid accrued interest on and principal balances of the 2011 HealthCor Notes into fully paid and non-assessable shares of our Common Stock has been eliminated. On January 31, 2012, we entered into the Second Amendment to the HealthCor Purchase Agreement with HealthCor (the “Second Amendment”) amending the HealthCor Purchase Agreement and sold Senior Secured Convertible Notes to HealthCor in the principal amounts of $2,329,000 and $2,671,000, respectively (collectively the “2012 HealthCor Notes”). As provided by the Second Amendment, the 2012 HealthCor Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the “Issuance Date,” “Maturity Date,” “First Five-Year Note Period” and other terms to take into account the timing of the issuance of the 2012 HealthCor Notes. The 2012 HealthCor Notes have a maturity date of January 30, 2022. In addition, the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the 2011 HealthCor Notes. At any time after January 30, 2012, HealthCor is entitled to convert any portion of the outstanding and unpaid accrued interest on and principal balances of the 2012 HealthCor Notes into fully paid and non-assessable shares of our Common Stock at a conversion rate of $1.25 per share, subject to adjustment in accordance with anti-dilution provisions set forth in the 2012 HealthCor Notes. Pursuant to the terms of the Ninth Amendment, as discussed below, the accrual of interest has been suspended after September 30, 2018 On August 20, 2013, we entered into a Third Amendment to the HealthCor Purchase Agreement with HealthCor (the “Third Amendment”) to redefine our minimum cash balance requirements. Previously we were required to maintain a minimum cash balance of $5,000,000 and should we drop below that balance, it triggered a default. The Third Amendment allowed for a reduced minimum cash period, as defined in the HealthCor Purchase Agreement, which allowed us to drop below $5,000,000, but not below $4,000,000. All other terms and conditions of the HealthCor Purchase Agreement, including all amendments thereto, remain the same. Upon entering the reduced minimum cash period (which occurred on October 7, 2013), we had 120 days to return our minimum cash balance to the original $5,000,000. On January 16, 2014, we increased our cash balance to in excess of the original $5,000,000 minimum allowable balance. On January 16, 2014, we entered into a Fourth Amendment to the HealthCor Purchase Agreement with HealthCor (the “Fourth Amendment”) and sold Senior Secured Convertible Notes to HealthCor in the principal amounts of $2,329,000 and $2,671,000 (collectively the ‘‘2014 HealthCor Notes’’). As provided by the Fourth Amendment, the 2014 HealthCor Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the “Issuance Date,” “Maturity Date,” “First Five-Year Note Period” and other terms to take into account the timing of the issuance of the 2014 HealthCor Notes. The 2014 HealthCor Notes have a maturity date of January 15, 2024. In addition, the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the 2011 HealthCor Notes. At any time after January 16, 2014, HealthCor is entitled to convert any portion of the outstanding and unpaid accrued interest on and principal balances of the 2014 HealthCor Notes into fully paid and non-assessable shares of our Common Stock at a conversion rate of $0.40 per share, subject to adjustment in accordance with anti-dilution provisions set forth in the 2014 HealthCor Notes. Additionally, we issued Warrants to HealthCor for the purchase of an aggregate of up to 4,000,000 shares of our Common Stock at an exercise price of $0.40 per share (collectively the “2014 HealthCor Warrants”). As of September 30, 2019, the underlying shares of our Common Stock related to the 2014 HealthCor Notes totaled approximately 25,000,000. On December 4, 2014, we entered into a Fifth Amendment to the HealthCor Purchase Agreement (the “Fifth Amendment”) with HealthCor and certain additional investors (such additional investors, the “2015 Investors” and, collectively with HealthCor, the “Investors”) and agreed to sell and issue (i) additional notes in the initial aggregate principal amount of $6,000,000,with a conversion price per share of $0.52 (subject to adjustment as described therein) (the “Fifth Amendment Notes”) and (ii) additional Warrants for an aggregate of up to 3,692,308 shares of our Common Stock at an exercise price per share of $0.52 (subject to adjustment as described therein) (the “Fifth Amendment Warrants”). As provided by the Fifth Amendment, the Fifth Amendment Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the “Issuance Date,” “Maturity Date,” “First Five-Year Note Period” and other terms to take into account the timing of the issuance of the Fifth Amendment Notes. The Fifth Amendment Notes have a maturity date of February 16, 2025. In addition, the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the 2011 HealthCor Notes. The 2015 Investors are composed of all but one of our current directors and one of our officers. On February 17, 2015, the Company and the Investors closed on the transactions contemplated by the Fifth Amendment. In connection with this closing, the Company and the Investors entered into an Amended and Restated Pledge and Security Agreement (the “Amended Security Agreement”), amending and restating that certain Pledge and Security Agreement dated as of April 20, 2011, and an Amended and Restated Intellectual Property Security Agreement (the “Amended IP Security Agreement”), amending and restating that certain Intellectual Property Security Agreement dated as of April 20, 2011. As of September 30, 2019, the underlying shares of our Common Stock related to the Fifth Amendment Notes totaled approximately 3,000,000 to HealthCor and 17,000,000 to the 2015 Investors. On March 31, 2015, we entered into the Sixth Amendment to the HealthCor Purchase Agreement (the “Ninth Amendment”) pursuant to which, among other things, (i) the requirement to maintain a minimum cash balance of $5,000,000 was reduced to a minimum cash balance of $2,000,000 and (ii) the amendment provision was revised to permit the HealthCor Purchase Agreement to be amended by the Company and the holders of the majority of the Common Stock underlying the outstanding notes and warrants to purchase shares of our Common Stock sold pursuant to the HealthCor Purchase Agreement. On March 31, 2015, we also issued a warrant to HealthCor to purchase up to an aggregate of 1,000,000 shares of our Common Stock in consideration for certain prior waivers of the minimum cash balance requirement in the HealthCor Purchase Agreement (the “Ninth Amendment Warrant”). The Ninth Amendment Warrant has an exercise price per share of $0.53 (subject to adjustment as described therein) and an expiration date of March 31, 2025. On June 26, 2015, we (i) entered into a Seventh Amendment to the HealthCor Purchase Agreement (the “Seventh Amendment”) pursuant to which the HealthCor Purchase Agreement was amended to permit the Company to enter into and perform its obligations under the PDL Credit Agreement (as detailed in NOTE 9); (ii) executed an Amendment to the Registration Rights Agreement between the Company and HealthCor dated April 21, 2011 (the “RR Agreement”) pursuant to which the RR Agreement was amended to make its priority of registration consistent with the Registration Rights Agreement executed by the Company and PDL; (iii) amended the 2011 HealthCor Notes to extend the maturity date, in the event that Tranche Two of the PDL Credit Agreement is funded, for such notes to 90 days after the earlier of the Tranche Two maturity date or repayment date, but not later than December 31, 2022, (iv) amended the 2012 HealthCor Notes, to set the maturity date at January 30, 2022 and, in the event that Tranche Two of the PDL Credit Agreement is funded, to extend such maturity date to 90 days after the earlier of the Tranche Two maturity date or repayment date, but later than December 31, 2022; and (v) amended each of the Senior Secured Convertible Notes issued under the HealthCor Purchase Agreement (the “HealthCor Notes”) to, among other things, subordinate the HealthCor Notes to the loans under the PDL Credit Agreement and to increase certain event of default acceleration and payment thresholds. ). As pertains to (iii) and (iv) above, pursuant to the terms of the PDL Credit Agreement and having not met the Tranche Two Milestones by July 26, 2017, the Tranche Two funding was terminated in full. On February 23, 2018, we entered into an Eighth Amendment to the HealthCor Purchase Agreement (the “Eighth Amendment”) with HealthCor, the 2015 Investors and certain investors (such additional investors, the “February 2018 Investors”) and agreed to sell and issue (i) additional notes in the initial aggregate principal amount of $2,050,000,with a conversion price per share of $0.05 (subject to adjustment as described therein) (the “Eighth Amendment Notes”) and (ii) additional Warrants for an aggregate of up to 512,500 shares of our Common Stock at an exercise price per share of $0.05 (subject to adjustment as described therein) (the “Eighth Amendment Warrants”). As provided by the Eighth Amendment, the Eighth Amendment Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the “Issuance Date,” “Maturity Date,” “First Five-Year Note Period” and other terms to take into account the timing of the issuance of the Eighth Amendment Notes. The Eighth Amendment Notes have a maturity date of February 22, 2028. In addition, the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the 2011 HealthCor Notes. The 2018 Investors are composed of all but one of our current directors, one of our officers and an entity. As of September 30, 2019, the underlying shares of our Common Stock related to the Eighth Amendment Notes totaled approximately 50,000,000 to the February 2018 Investors. On July 10, 2018, we entered into the Ninth Amendment to the HealthCor Purchase Agreement (the “Ninth Amendment”) with HealthCor, the 2015 Investors and the February 2018 Investors, pursuant to which the parties agreed to amend the HealthCor Purchase Agreement, the 2011 HealthCor Notes, the 2012 HealthCor Notes, the 2014 HealthCor Notes, the Fifth Amendment Notes and the Eighth Amendment Notes, as applicable, to (i) remove the rights of the holders of the 2011 HealthCor Notes and the 2012 HealthCor Notes to convert such notes to Common Stock after September 30, 2018; (ii) suspend the accrual of interest on the 2011 HealthCor Notes and the 2012 HealthCor Notes for periods after September 30, 2018; (iii) provide for the potential earlier repayment of the 2011 HealthCor Notes and the 2012 HealthCor Notes by the Company, 120 calendar days following a written demand for payment by the holder of such notes; provided, however, that such written demand may not be given prior to the twelve-month anniversary of the date on which the obligations of the Company under the PDL Credit Agreement are repaid in full; (iv) cancel the 2011 HealthCor Warrants; (v) provide for the seniority of the 2011 HealthCor Notes and the 2012 HealthCor Notes in right of payment over notes subsequently issued pursuant to the Purchase Agreement, including the 2014 HealthCor Notes, the Fifth Amendment Notes and the Eighth Amendment Notes; (vi) amend the terms of the 2014 HealthCor Notes, the Fifth Amendment Notes and the Eighth Amendment Notes to reflect the seniority in payment of the 2011 HealthCor Notes and 2012 HealthCor Notes; and (vii) reduce the number of shares of Common Stock that the Company must at all times have authorized and reserved for the purpose of issuance upon conversion of the notes issued pursuant to the HealthCor Purchase Agreement (collectively, the “Notes”) and exercise of the warrants issued pursuant to the HealthCor Purchase Agreement (collectively, the “Warrants”), from at least 120% of the aggregate number of shares of Common Stock then issuable upon full conversion of the Notes and exercise of the Warrants to at least 100% of such aggregate number of shares. In addition, on July 10, 2018, along with PDL, HealthCor, the 2015 Investors and the February 2018 Investors, we entered into a Second Amendment to the Subordination and Intercreditor Agreement, to amend the Subordination and Intercreditor Agreement dated as of September 26, 2015, as amended to provide that, in the event of a sale of the Company’s hospital assets, after the net proceeds are first applied to repay obligations under the PDL Credit Agreement, as amended, until paid in full, up to the next $5,000,000 of such net proceeds may be retained by the Company for working capital purposes before all remaining net proceeds are then applied to repay the obligations under the Notes in accordance with the priorities set forth in the HealthCor Purchase Agreement and the Notes. On July 13, 2018, we entered into the Tenth Amendment to the HealthCor Purchase Agreement with HealthCor, the 2015 Investors, the February 2018 Investors and certain investors (all of which are directors of the Company) (such additional investors, the “July 2018 Investors”), pursuant to which we sold and issued convertible secured promissory notes for an aggregate of $1,000,000 to the July 2018 Investors with a conversion price per share equal to $0.05 (subject to adjustment as described therein) (the “Tenth Amendment Notes”) . On March 27, 2019, we entered into the Eleventh Amendment to the HealthCor Purchase Agreement, as amended, with HealthCor, the 2015 Investors, the February 2018 Investors and the July 2018 Investors, pursuant to which all parties agreed to amend and restate Section 5.3 Minimum Cash Balance (“Section 5.3”), wherein the requirement of maintaining a minimum cash balance has been removed and any breach of Section 5.3 has been waived in perpetuity. On May 15, 2019, we entered into the Twelfth Amendment to HealthCor Purchase Agreement with HealthCor, the 2015 Investors, the February 2018 Investors, the July 2018 Investors, and an investor (a member of our board of directors) (such additional investor, the “2019 Investor”), pursuant to which we sold and issued a convertible secured promissory note for $50,000 to the 2019 Investor with a conversion price per share equal to $0.03 (subject to adjustment as described therein) (the “Twelfth Amendment Note”) . As provided by the Twelfth Amendment, the Twelfth Amendment Notes are in substantially the same form as the 2011 HealthCor Notes, with changes to the “Issuance Date,” “Maturity Date,” “First Five-Year Note Period” and other terms to take into account the timing of the issuance of the Twelfth Amendment Notes. The Twelfth Amendment Notes have a maturity date of May 15, 2029. In addition, the provisions regarding interest payments, interest acceleration, optional conversion, negative covenants, and events of default, preemptive rights and registration rights are the same as those of the 2011 HealthCor Notes. As of September 30, 2019, the underlying shares of our Common Stock related to the Twelfth Amendment Note totaled approximately 2,000,000 to the 2019 Investor. Accounting Treatment When issuing debt or equity securities convertible into common stock at a discount to the fair value of the common stock at the date the debt or equity financing is committed, a company is required to record a beneficial conversion feature (“BCF”) charge. We had three separate issuances of equity securities convertible into common stock that qualify under this accounting treatment, (i) the 2011 HealthCor Notes, (ii) the 2012 HealthCor Notes and (iii) the 2014 HealthCor Notes. Because the conversion option and the 2011 HealthCor Warrants on the 2011 HealthCor Notes were originally classified as a liability when issued due to the down round provision and the removal of the provision requiring liability treatment, and subsequently reclassified to equity on December 31, 2011 when the 2011 HealthCor Notes were amended, only the accrued interest capitalized as payment in kind (‘‘PIK’’) since reclassification qualifies under this accounting treatment. We recorded an aggregate of $3,289,639 and $2,746,081 in interest for the nine months ended September 30, 2019 and 2018, respectively, related to these transactions. The face amount of the 2012 HealthCor Notes, 2014 HealthCor Notes, the Fifth Amendment Notes and the Eighth Amendment Notes and all accrued PIK interest also qualify for BCF treatment as discussed above. Under the accounting standards, we determined that the restructuring of the HealthCor notes, pursuant to the terms of the Ninth Amendment, resulted in a troubled debt restructuring. As the future cash flows were greater than the carrying amount of the debt at the date of the amendment, we accounted for the change prospectively using the new effective interest rate. During the nine months ended September 30, 2019 and 2018, we recorded a BCF of $51,123 and $98,363, respectively. The BCF was recorded as a charge to debt discount and a credit to additional paid in capital, with the debt discount, using the effective interest method, amortized to interest expense over the term of the notes. As Warrants were issued with the Fifth Amendment Notes, the proceeds were allocated to the instruments based on relative fair value as the warrants did not contain any features requiring liability treatment and therefore were classified as equity. The value allocated to the Fifth Amendment Warrants was $1,093,105, which was recorded as debt discount with the credit to additional paid in capital. We recorded an aggregate of $25,443 and $21,456 in interest for the nine months ended September 30, 2019 and 2018, respectively, related to the Fifth Amendment Notes and Fifth Amendment Warrants. The carrying value of the Fifth Amendment Notes at December 31, 2018 approximates fair value as the interest rates used are those currently available to us and would be considered level 3 inputs under the fair value hierarchy. The Sixth Amendment Warrants also did not contain features requiring liability accounting and were recorded at fair value on the date of issuance with the offsetting credit recorded in equity. The value allocated to the Sixth Amendment Warrant was $378,000, which was recorded as debt costs with the credit to additional paid in capital. We recorded an aggregate of $43,352 and $43,352 in interest expense for the nine months ended September 30, 2019 and 2018, respectively. The Eighth Amendment Warrants also did not contain features requiring liability accounting and were recorded at fair value on the date of issuance with the offsetting credit recorded in equity. The value allocated to the Eighth Amendment Warrants was $10,707, which was recorded as interest expense at September 30, 2019. At September 30, 2019, total HealthCor and Other investor debt outstanding was of $69,638,663 presented on the accompanying consolidated financial statements as long-term and net of debt discount of $11,196,481.

JOINT VENTURE AGREEMENT

JOINT VENTURE AGREEMENT	9 Months Ended
	Sep. 30, 2019
Equity Method Investments and Joint Ventures [Abstract]
JOINT VENTURE AGREEMENT	NOTE 11 – JOINT VENTURE AGREEMENT On November 16, 2009, we entered into a Master Investment Agreement (the “Rockwell Agreement”) with Rockwell Holdings I, LLC, a Wisconsin limited liability (“Rockwell”). Under the terms of the Rockwell Agreement, we used funds from Rockwell to fully implement the CareView System™ in Hillcrest Medical Center in Tulsa, Oklahoma (“Hillcrest”) and Saline Memorial Hospital in Benton, Arkansas (“Saline”) (the “Project Hospital(s)”). CareView-Hillcrest, LLC and CareView-Saline, LLC were created as the operating entities for the Project Hospitals under the Rockwell Agreement (the “Project LLCs”). On January 31, 2017, under the terms of the Rockwell Agreement, wherein we had the option to purchase Rockwell’s interest in the Project LLCs, we exercised that right by entering into a Settlement and LLC Interest Purchase Agreement with Rockwell (the “Settlement Agreement). Pursuant to the terms of the Settlement Agreement, we paid Rockwell the aggregate amount of $1,213,786 by the issuance of a promissory note to Rockwell for $1,113,786 (the “Rockwell Note”) and a cash payment of $100,000. Pursuant to the terms of the Rockwell Note, we were to make quarterly principal payments of $100,000, with each payment being made on the last day of each calendar quarter beginning with the first payment date of March 31, 2017 and continuing on the last business day of each subsequent quarter through September 30, 2019. The final payment due on December 31, 2019 was to be a balloon payment of $13,786 representing the remaining principal balance plus all accrued and unpaid interest. Effective February 2, 2018, pursuant to the terms of the PDL Modification Agreement, as amended, we entered into an amendment to the Rockwell Note wherein the quarterly payments under the Rockwell Note were reduced to $50,000 per quarter, through the end of the PDL Modification Period, September 30, 2019. The final balloon payment of $461,287 representing the remaining principal plus all accrued and unpaid interest is due on December 31, 2019. We were not in default of any conditions under the Settlement Agreement and amended Rockwell Note as of September 30, 2019. As additional consideration to Rockwell for entering into the Rockwell Agreement, we granted Rockwell Warrants to purchase 1,151,206 shares of our Common Stock on the date of the Rockwell Agreement, and, using the Black-Scholes Model, valued the Warrants at $1,124,728 (the “Project Warrant”), which amount was fully amortized at December 31, 2015. Pursuant to the terms of the Settlement Agreement, the expiration date of the Project Warrant was extended from November 16, 2017 to November 16, 2022. All other provisions of the Project Warrant remained unchanged. At the time of the extension, the Project Warrant were revalued resulting in a $11,512 increase in fair value, which has been recorded as non-cash costs included in general and administration expense in the accompanying condensed consolidated financial statements. Effective February 2, 2018, pursuant to the terms of the PDL Modification Agreement, we entered into an amendment to the Project Warrant wherein the Project Warrant’s exercise price was changed from $0.52 to $0.05, resulting in a $13,814 increase in fair value, which was recorded as non-cash costs included in general and administration expense in the consolidated financial statements for the year ended December 31, 2018. At September 30, 2019, total Rockwell debt outstanding was $363,786 presented as current on the accompanying consolidated financial statements.

BASIS OF PRESENTATION AND REC_2

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Interim Financial Statements	Interim Financial Statements The accompanying unaudited interim condensed consolidated financial statements of CareView Communications, Inc. (“CareView”, the “Company”, “we”, “us” or “our”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, such financial statements include all adjustments (consisting solely of normal recurring adjustments) necessary for the fair statement of the financial information included herein in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission (the “SEC”). The balance sheet at December 31, 2018 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates. Results of operations for interim periods are not necessarily indicative of results for the full year. The accompanying condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the SEC on March 29, 2019.
Revenue Recognition	Revenue Recognition We adopted Accounting Standards Codification (“ASC”) Topic 606 (“ASC 606”) on January 1, 2018 using the full retrospective transition method for recognizing revenue. The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of our services to our customers and will provide financial statement readers with enhanced disclosures. We have employed the practical expedient discussed in ASC 606-10-55-18 related to invoicing as we have the right to consideration from our customers in the amount that corresponds directly with the value to the customer of our performance completed to date and therefore we recognize revenue upon invoicing as further discussed below. Further, for those customers for which we are required to collect sales taxes, we record such sales taxes on a net basis which has no effect on the amount of revenue or expenses recognized as the sales taxes are a flow through to the taxing authority. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation. We offer CareView’s services through a subscription-based contract with each healthcare facility for a standard term of three to five years and have determined we have one performance obligation for our services. We begin to bill monthly subscription fees to the healthcare facility upon official acceptance of the CareView System by the healthcare facility which is when the service is initiated. When services begin, the customer simultaneously receives the use and benefit of that service and we recognize the revenue over time based on the service completed to date as the amount invoiced each month. The contract requires the healthcare facility to pay us the subscription fee monthly. During the term of the contract, we provide continuous monitoring of the CareView System and are required to maintain and service all CareView System equipment. If the healthcare facility requires additional services, the contract is amended accordingly. The company evaluated the disaggregation criteria of ASC 606 and determine that based on the nature, amount, timing and uncertainty of our service revenues, there were no material differences that merited further disaggregation as compared to the total revenue as reported in the accompanying consolidated statements of operations. We defer and capitalize all costs associated with the installation of the CareView System into a healthcare facility until the CareView System is fully operational and accepted by the healthcare facility. Installation costs are specifically identifiable based on the amounts we are charged from third party installers or directly identifiable labor hours incurred for each installation. Upon acceptance, the associated costs are expensed on a straight-line basis over the life of the contract with the healthcare facility. These costs are included in network operations on the accompanying consolidated statements of operations. The table below details the activity in these deferred installation costs during the nine months ended September 30, 2019 and 2018. Nine Months Ended 2019 2018 Balance, beginning of period $ 134,686 $ 215,548 Additions 47,472 56,401 Transfer to expense (67,360 ) (115,088 ) Balance, end of period $ 114,798 $ 156,861 From time to time, we enter into contracts with healthcare facilities wherein full payment of the contractual obligation is paid in advance (“PIA Contracts”). The transaction is recorded as a contract liability in our consolidated financial statements, with revenue recorded and the contract liability reduced as services are provided under the contract. The table below details this activity during the nine months ended September 30, 2019 and 2018. Nine Months Ended 2019 2018 Balance, beginning of period $ 58,559 $ 17,430 Additions 175,370 192,507 Transfer to revenue (131,527 ) (107,535 ) Balance, end of period $ 102,402 $ 102,402 Based on our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. Accordingly, except in the case of PIA Contracts as detailed above, our contracts do not give rise to contract assets or liabilities under ASC 606. Accounts receivable are recorded when the right to consideration becomes unconditional and are reported accordingly on our consolidated financial statements.
Accounting Standard Update 2016-02, Leases	Accounting Standard Update 2016-02, Leases Under Topic 842, operating lease expense is generally recognized evenly over the term of the lease. The Company has an operating lease primarily consisting of office space with remaining lease terms of 12 months. We adopted Accounting Standard Update (“ASU”) 2016-02, Leases using the cumulative effect transition method for all long-term operating leases as of January 1, 2019. The cumulative impact of the adoption of ASU 2016-02 to the condensed consolidated balance sheet as of January 31, 2019 was as follows: Right to Use Asset $ 236,959 Right to Use Liability-ST $ 166,955 Right to Use Liability-LT $ 83,477 The adoption of ASU 2016-02 did not result in an adjustment to retained earnings. The adoption of ASU-2016-02 represents a change in accounting principle.
Earnings Per Share	Earnings Per Share We calculate earnings per share (“EPS”) in accordance with GAAP, which requires the computation and disclosure of two EPS amounts, basic and diluted. Basic EPS is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted EPS is computed based on the weighted average number of common shares outstanding plus all potentially dilutive common shares outstanding during the period under the treasury stock method. Such potential dilutive common shares consist of stock options, warrants and convertible debt. Potential common shares totaling approximately 157,000,000 and 189,000,000 at September 30, 2019 and 2018, respectively, have been excluded from the diluted earnings per share calculation as they are anti-dilutive due to our reported net loss.
CareView Connect	CareView Connect CareView Connect is a platform consisting of several products and applications targeted at improving level of care and efficiency. We offer an array of wearable and stationary buttons that allow a resident to summon help either for an emergency or assistance, which can be anything from toileting help to assistance putting on their shoes. We offer a mobile app capable of delivering an alert to the caregiver and allows them document information around that alert. This allows for workflows and reports around the alerts, i.e. how long before the alert was handled, what was the cause of the alert, and if not acknowledged in a timely manner then escalate the alert to another individual or group. This ensures that every alert is responded to timely and is verifiable. The decision as to how the Company will distribute CareView Connect has yet to be determined. Our options include direct sales to the end user, lease/buy purchase plans, or the Company may retain ownership and bill for monitoring services, or a combination of these options. Pending the final distribution decision, the equipment included in the CareView Connect product line is recorded as prepaid equipment on the accompanying condensed consolidated financial statements. Once the distribution decision is made, the CareView Connect equipment will be transferred to inventory or deployable fixed assets as appropriate.
Recently Issued and Newly Adopted Accounting Pronouncements	Recently Issued and Newly Adopted Accounting Pronouncements Aside from the change noted in Leases NOTE 2

BASIS OF PRESENTATION AND REC_3

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Tables)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Schedule of deferred installation costs	The table below details the activity in these deferred installation costs during the nine months ended September 30, 2019 and 2018. Nine Months Ended 2019 2018 Balance, beginning of period $ 134,686 $ 215,548 Additions 47,472 56,401 Transfer to expense (67,360 ) (115,088 ) Balance, end of period $ 114,798 $ 156,861
Schedule of details of contract liabilities	The table below details this activity during the nine months ended September 30, 2019 and 2018. Nine Months Ended 2019 2018 Balance, beginning of period $ 58,559 $ 17,430 Additions 175,370 192,507 Transfer to revenue (131,527 ) (107,535 ) Balance, end of period $ 102,402 $ 102,402
Schedule of cumulative impact of the adoption of ASU 2016-02 to the condensed consolidated balance sheet	The cumulative impact of the adoption of ASU 2016-02 to the condensed consolidated balance sheet as of January 31, 2019 was as follows: Right to Use Asset $ 236,959 Right to Use Liability-ST $ 166,955 Right to Use Liability-LT $ 83,477

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	9 Months Ended
	Sep. 30, 2019
Stockholders' Equity Note [Abstract]
Schedule of stock option activity	A summary of our stock option activity and related information follows: Number of Shares Under Options Weighted Average Exercise Price Weighted Aggregate Intrinsic Value Balance at December 31, 2018 21,700,293 $ 0.27 7.1 $ — Expired (938,665 ) Canceled (40,000 ) Balance at September 30, 2019 20,721,628 $ 0.25 6.5 $ — Vested and Exercisable at September 30, 2019 14,082,298 $ 0.33 5.8 $ —

OTHER CURRENT ASSETS (Tables)

OTHER CURRENT ASSETS (Tables)	9 Months Ended
	Sep. 30, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of other current assets	Other current assets consist of the following: September 30, December 31, 2018 Prepaid equipment $ 1,283,309 $ 1,327,156 Oher prepaid expenses 166,246 66,888 Other current assets 13,530 14,382 TOTAL OTHER CURRENT ASSETS $ 1,463,085 $ 1,408,426

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	Property and equipment consist of the following: September 30, December 31, 2018 Network equipment $ 12,388,147 $ 12,302,328 Office equipment 305,250 293,709 Vehicles 217,004 217,004 Test equipment 192,384 175,603 Furniture 91,341 90,827 Warehouse equipment 9,524 9,524 Leasehold improvements 5,121 5,121 13,208,771 13,094,116 Less: accumulated depreciation (11,107,996 ) (10,607,450 ) TOTAL PROPERTY AND EQUIPMENT $ 2,100,775 $ 2,486,666

OTHER ASSETS (Tables)

OTHER ASSETS (Tables)	9 Months Ended
	Sep. 30, 2019
Other Assets:
Schedule of intangible assets	Intangible assets consist of the following: September 30, 2019 Cost Accumulated Amortization Net Patents and trademarks $ 1,022,064 $ 229,448 $ 792,616 Other intangible assets 63,509 59,121 4,388 TOTAL INTANGIBLE ASSETS $ 1,085,573 $ 288,569 $ 797,004 December 31, 2018 Cost Accumulated Amortization Net Patents and trademarks $ 932,149 $ 192,995 $ 739,154 Other intangible assets 63,508 56,522 6,986 TOTAL INTANGIBLE ASSETS $ 995,657 $ 249,517 $ 746,140
Schedule of other assets	Other assets consist of the following: September 30, 2019 Cost Accumulated Amortization Net Deferred installation costs $ 1,857,886 $ 1,743,088 $ 114,798 Prepaid license fee 249,999 132,513 117,486 Security deposit 46,124 — 46,124 TOTAL OTHER ASSETS $ 2,154,009 $ 1,875,601 $ 278,408 Other assets consist of the following: December 31, 2018 Cost Accumulated Amortization Net Deferred installation costs $ 1,810,414 $ 1,675,728 $ 134,686 Prepaid license fee 249,999 120,217 129,782 Security deposit 46,124 — 46,124 TOTAL OTHER ASSETS $ 2,106,537 $ 1,795,945 $ 310,592

OTHER CURRENT LIABILITIES (Tabl

OTHER CURRENT LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2019
Payables and Accruals [Abstract]
Schedule of other current liabilities	Other current liabilities consist of the following: September 30, December 31, 2018 Accrued interest $ 2,963,381 $ 750,548 Deferred commission 139,041 117,206 Accrued paid time off 108,999 129,773 Deferred revenue 102,402 58,559 Allowance for system removal 101,100 236,650 Accrued insurance 77,440 — Other accrued liabilities 64,860 31,568 Accrued taxes 64,763 23,156 Accrued rent expense — 68,780 TOTAL OTHER CURRENT LIABILITIES $ 3,621,985 $ 1,416,240

BASIS OF PRESENTATION AND REC_4

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Accounting Policies [Abstract]
Deferred installation costs, beginning	$ 134,686	$ 215,548
Additions	47,472	56,401
Transfer to expense	(67,360)	(115,088)
Deferred installation costs, ending	$ 114,798	$ 156,861

BASIS OF PRESENTATION AND REC_5

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details 1) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Accounting Policies [Abstract]
Contract liabilities, beginning	$ 58,559	$ 17,430
Additions	175,370	192,507
Transfer to revenue	(131,527)	(107,535)
Contract liabilities, ending	$ 102,402	$ 102,402

BASIS OF PRESENTATION AND REC_6

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details 2) - USD ($)	Sep. 30, 2019	Jan. 31, 2019
Right to Use Asset	$ 126,182
Right to Use Liability-ST	$ 134,313
ASU 2016-02 [Member]
Right to Use Asset		$ 236,959
Right to Use Liability-ST		166,955
Right to Use Liability-LT		$ 83,477

BASIS OF PRESENTATION AND REC_7

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Accounting Policies [Abstract]
Anti-dilutive common share equivalents excluded from EPS calculation	157,000,000	189,000,000
Lease terms	12 months

GOING CONCERN, LIQUIDITY AND _2

GOING CONCERN, LIQUIDITY AND MANAGMENTS PLAN (Details Narrative) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Going Concern Liquidity And Managments Plan
Cash and cash equivalents	$ 926,249	$ 1,200,725

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details) - $ / shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Number Options
Stock Options Outstanding, Beginning	21,700,293
Expired	(938,665)	(686,836)
Canceled	(40,000)	(214,997)
Stock Options Outstanding, Ending	20,721,628
Stock Options, Vested and Exercisable	14,082,298
Weighted Average Exercise Price
Stock Options Outstanding, Beginning	$ 0.27
Stock Options Outstanding, Ending	0.25
Stock Options, Vested and Exercisable	$ 0.33
Weighted Average Remaining Contractual Life
Stock Options Outstanding, Beginning	7 years 1 month 6 days
Stock Options Outstanding, Ending	6 years 6 months
Stock Options, Vested and Exercisable	5 years 9 months 18 days

STOCKHOLDERS' EQUITY (Details N

STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	May 15, 2019	Apr. 11, 2019	Dec. 31, 2018	Jul. 10, 2018	Mar. 31, 2018	Feb. 23, 2018
Common stock, par value (in dollars per share)	$ 0.001				$ 0.001
Common stock, authorized	500,000,000				300,000,000
Common stock, issued	139,380,748				139,380,748
Warrant activity
Number of warrant issued								487,500
Warrant exercise price (in dollars per share)								$ 0.05
Fair value of the warrants								$ 10,237
Waarant term								10 years
Option activity
Option expired	938,665	686,836
Options canceled	40,000	214,997
Share-based compensation expense	$ 158,866	$ 206,114
Unrecognized estimated compensation expense	$ 107,000
Period for recognition of unrecognized compensation expense	1 year
HealthCor Purchase Agreement [Member]
Warrant activity
Number of warrant issued						11,782,859
Private Placement [Member]
Warrant activity
Number of warrant issued							2,500,000
Fair value of the warrants							$ 11,157
Directors And Officers [Member]
Warrant activity
Number of warrant issued								25,000
Warrant exercise price (in dollars per share)								$ 0.05
Fair value of the warrants								$ 525
Waarant term								10 years
Director [Member]
Warrant activity
Number of warrant issued			250,000
Warrant exercise price (in dollars per share)			$ 0.03
Fair value of the warrants			$ 4,000
Waarant term			10 years
Charter Amendment [Member]
Common stock, par value (in dollars per share)				$ 0.001
Common stock, authorized				300,000,000
Common stock, issued			72,863,770
Ownership [Member] | Charter Amendment [Member]
Ownership precentage			52.00%

OTHER CURRENT ASSETS (Details)

OTHER CURRENT ASSETS (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid equipment	$ 1,283,309	$ 1,327,156
Other prepaid expenses	166,246	66,888
Other current assets	13,530	14,382
TOTAL OTHER CURRENT ASSETS	$ 1,463,085	$ 1,408,426

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 13,208,771	$ 13,094,116
Less: accumulated depreciation	(11,107,996)	(10,607,450)
Property and equipment, net	2,100,775	2,486,666
Network Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	12,388,147	12,302,328
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	305,250	293,709
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	217,004	217,004
Test Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	192,384	175,603
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	91,341	90,827
Warehouse Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	9,524	9,524
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 5,121	$ 5,121

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 500,546	$ 985,927

OTHER ASSETS (Details)

OTHER ASSETS (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Cost	$ 1,085,573	$ 995,657
Accumulated Amortization	288,569	249,517
Net	797,004	746,140
Patents and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	1,022,064	932,149
Accumulated Amortization	229,448	192,995
Net	792,616	739,154
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	63,509	63,508
Accumulated Amortization	59,121	56,522
Net	$ 4,388	$ 6,986

OTHER ASSETS (Details 1)

OTHER ASSETS (Details 1) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Cost	$ 2,154,009	$ 2,106,537
Accumulated Amortization	1,875,601	1,795,945
Net	278,408	310,592
Deferred Installation Costs [Member]
Cost	1,857,886	1,810,414
Accumulated Amortization	1,743,088	1,675,728
Net	114,798	134,686
Prepaid License Fee [Member]
Cost	249,999	249,999
Accumulated Amortization	132,513	120,217
Net	117,486	129,782
Security Deposit [Member]
Cost	46,124	46,124
Net	$ 46,124	$ 46,124

OTHER CURRENT LIABILITIES (Deta

OTHER CURRENT LIABILITIES (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
OTHER CURRENT LIABILITIES:
Accrued interest	$ 2,963,381	$ 750,548
Deferred commission	139,041	117,206
Accrued paid time off	108,999	129,773
Deferred revenue	102,402	58,559
Allowance for system removal	101,100	236,650
Accrued insurance	77,440
Other accrued liabilities	64,860	31,568
Accrued taxes	64,763	23,156
Accrued rent expense		68,780
TOTAL OTHER CURRENT LIABILITIES	$ 3,621,985	$ 1,416,240

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Operating Loss Carryforwards [Line Items]
Statutory federal tax rate (in percent)	35.00%	21.00%
Federal [Member]
Operating Loss Carryforwards [Line Items]
Percentage of net operating tax loss carry-forward	80.00%

AGREEMENT WITH PDL BIOPHARMA,_2

AGREEMENT WITH PDL BIOPHARMA, INC. (Details Narrative) - USD ($)

May 15, 2019

Apr. 29, 2019

Apr. 09, 2019

Mar. 29, 2019

Feb. 28, 2019

Jan. 31, 2019

Dec. 28, 2018

Jun. 26, 2015

Feb. 28, 2018

Jan. 31, 2018

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

May 13, 2019

Feb. 23, 2018

Dec. 28, 2017

Oct. 09, 2015

Warrant exercise price (in dollars per share)

$ 0.05

Restricted cash

$ 750,000

Interest Expense

$ 2,769,755

$ 2,438,627

$ 8,173,586

$ 9,707,423

PDL Modification Agreement [Member]

Reduction in monthly operating expenses

$ 148,000

$ 113,000

$ 167,000

Accrued interest

2,858,611

2,858,611

Deferred issuance costs

92,102

92,102

Fifth PDL Credit Agreement Amendment [Member]

Interest rate

15.50%

Tenth Amendment PDL Modification Agreement [Member] | February 23, 2018 [Member]

Net cash proceeds for issuance capital stock or debt

$ 2,050,000

Eleventh Amendment PDL Modification Agreement [Member] | July 13, 2018 [Member]

Net cash proceeds for issuance capital stock or debt

$ 750,000

Twelfth Amendment PDL Modification Agreement [Member] | May 15, 2019 [Member]

Net cash proceeds for issuance capital stock or debt

$ 750,000

PDL Credit Agreement [Member]

Amount available under credit agreement

$ 40,000,000

Interest only quarterly payments

$ 675,000

Deferred issuance costs

92,000

92,000

Deferred financing costs

815,062

815,062

Debt outstanding

20,000,000

20,000,000

PDL Credit Agreement [Member] | Purchase Agreement Warrants [Member]

Warrants granted (shares)

4,444,445

Warrant exercise price (in dollars per share)

$ 0.45

$ 0.40

Deferred issuance costs

$ 1,257,778

Deferred financing costs

$ 44,445

Fourteenth PDL Modification Agreement [Member] | Upper Range [Member]

Minimum cash balance required under existing loan documents

$ 750,000

Fourteenth PDL Modification Agreement [Member] | Lower Range [Member]

Minimum cash balance required under existing loan documents

0

Fourteenth Amendment ToThe PDL Modification Agreement [Member]

Net cash proceeds for issuance capital stock or debt

750,000

$ 20,000,000

Fourteenth Amendment ToThe PDL Modification Agreement [Member] | On or prior to Feb. 28, 2019 [Member]

Net cash proceeds for issuance capital stock or debt

750,000

Fourteenth Amendment ToThe PDL Modification Agreement [Member] | On or prior to May 15, 2019 [Member]

Net cash proceeds for issuance capital stock or debt

3,300,000

Fourteenth Amendment ToThe PDL Modification Agreement [Member] | On or prior to July 13, 2018 [Member]

Net cash proceeds for issuance capital stock or debt

1,000,000

Fourteenth Amendment ToThe PDL Modification Agreement [Member] | On or prior to February 23, 2018 [Member]

Net cash proceeds for issuance capital stock or debt

2,050,000

Thirteen Amendment PDL Modification Agreement [Member] | May 15, 2019 [Member]

Net cash proceeds for issuance capital stock or debt

$ 3,550,000

Fifth PDL Modification Agreement [Member]

Interest Expense

$ 200,712

$ 75,240

722,959

$ 225,720

Tranche Three Loans Term Note [Member] | Fifth PDL Credit Agreement Amendment [Member] | Dr. Higgins [Member]

Note amount

50,000

Tranche Three Loans Term Note [Member] | Fifth PDL Credit Agreement Amendment [Member] | Mr. Johnson [Member]

Note amount

$ 150,000

Tranche One Loan Term Note [Member] | Fifth PDL Credit Agreement Amendment [Member]

Interest rate

13.50%

Tranche One Term Note [Member]

Principal payments

$ 1,666,667

Tranche One Term Note [Member] | Fifth PDL Credit Agreement Amendment [Member]

Warrant exercise price (in dollars per share)

$ 0.03

Interest rate

15.50%

Maturity date

Oct. 7, 2020

Note amount

$ 200,000

Issuance of warrants

250,000

PDL Credit Agreement - Tranche One Debt [Member]

Amount available under credit agreement

$ 20,000,000

Interest rate

13.50%

Tranche Three Lenders Term Note [Member] | Fifth PDL Modification Agreement [Member] | Warrants [Member]

Interest Expense

$ 3,704

AGREEMENT WITH HEALTHCOR (Detai

AGREEMENT WITH HEALTHCOR (Details Narrative) - USD ($)	Jul. 13, 2018	Feb. 23, 2018	Sep. 30, 2015	Dec. 04, 2014	Jan. 31, 2012	Apr. 21, 2011
Exercise price of warrants		$ 0.05
HealthCor Tenth Amendment to Purchase Agreement [Member]
Note amount	$ 1,000,000
Debt Maturity Date	Jul. 12, 2028
Debt conversion price	$ 0.05
HealthCor Eighth Amendment Purchase Agreement [Member]
Note amount		$ 2,050,000
Debt Maturity Date		Feb. 22, 2028
Issuance of warrants		512,500
Exercise price of warrants		$ 0.05
Debt conversion price		$ 0.05
HealthCor Ninth Amendment Purchase Agreement [Member]
Debt Maturity Date			Mar. 31, 2025
Issuance of warrants			1,000,000
Exercise price of warrants			$ 0.53
HealthCor Fifth Amendment Purchase Agreement [Member]
Note amount				$ 6,000,000
Debt Maturity Date				Feb. 16, 2025
Issuance of warrants				3,692,308
Exercise price of warrants				$ 0.52
Debt conversion price				$ 0.52
HealthCor Second Amendment Purchase Agreement [Member] | 2012 Senior Secured Convertible Note#1 [Member]
Note amount					$ 2,329,000
Debt Maturity Date					Jan. 30, 2022
HealthCor Second Amendment Purchase Agreement [Member] | 2012 Senior Secured Convertible Note#2 [Member]
Note amount					$ 2,671,000
Debt Maturity Date					Jan. 30, 2022
HealthCor Second Amendment Purchase Agreement [Member] | 2012 Senior Secured Convertible Notes [Member]
Debt conversion price					$ 1.25
HealthCor Purchase Agreement [Member] | 2011 Senior Secured Convertible Note#2 [Member]
Note amount						$ 10,684,000
Debt Maturity Date						Apr. 20, 2021
Issuance of warrants						6,294,403
Exercise price of warrants						$ 1.40
HealthCor Purchase Agreement [Member] | 2011 Senior Secured Convertible Note#1 [Member]
Note amount						$ 9,316,000
Debt Maturity Date						Apr. 20, 2021
Issuance of warrants						5,488,456
Exercise price of warrants						$ 1.40
HealthCor Purchase Agreement [Member] | 2011 Senior Secured Convertible Notes [Member]
Increase in interest rate (per annum) should default occur						5.00%
Debt conversion price						$ 1.25
HealthCor Purchase Agreement [Member] | 2011 Senior Secured Convertible Notes [Member] | Second Five Year Note Period [Member]
Interest rate, provided no default						10.00%

AGREEMENT WITH HEALTHCOR (Det_2

AGREEMENT WITH HEALTHCOR (Details Narrative 1)

May 15, 2019USD ($)$ / shares

Jul. 13, 2018USD ($)$ / shares

Jul. 10, 2018USD ($)

Feb. 23, 2018USD ($)$ / sharesshares

Sep. 30, 2015USD ($)$ / sharesshares

Dec. 04, 2014USD ($)$ / sharesshares

Jan. 16, 2014USD ($)$ / sharesshares

Sep. 30, 2019USD ($)

Sep. 30, 2018USD ($)

Sep. 30, 2019USD ($)Numbershares

Sep. 30, 2018USD ($)

Dec. 31, 2018USD ($)

Aug. 20, 2013USD ($)

Exercise price of warrants | $ / shares

$ 0.05

Beneficial conversion features for senior secured convertible notes

$ 20,802

$ 98,363

Debt discount

$ 11,196,481

11,196,481

$ 14,431,614

Interest Expense

2,769,755

$ 2,438,627

8,173,586

9,707,423

Deferred debt costs

0

0

815,062

Senior secured convertible notes, net of debt discount and debt costs

69,638,663

$ 69,638,663

$ 64,374,606

HealthCor Twelfth Amendment Purchase Agreement [Member] | 2019 Investor [Member]

Note amount

$ 50,000

Debt Maturity Date

May 15, 2029

Debt conversion price | $ / shares

$ 0.03

HealthCor Twelfth Amendment Purchase Agreement [Member] | Common Stock [Member] | 2019 Investor [Member]

Issuance of warrants | shares

2,000,000

HealthCor Tenth Amendment to Purchase Agreement [Member]

Note amount

$ 1,000,000

Debt Maturity Date

Jul. 12, 2028

Debt conversion price | $ / shares

$ 0.05

HealthCor Ninth Amedment Purchase Agreement [Member]

Net proceeds to be retained from sale of hospital assets

$ 5,000,000

Cash proceeds of working capital stock and debt

$ 5,000,000

HealthCor Ninth Amedment Purchase Agreement [Member] | Common Stock [Member]

Conversion of notes

1.20

HealthCor Ninth Amedment Purchase Agreement [Member] | Warrants [Member]

Conversion of notes

1

HealthCor Eighth Amendment Purchase Agreement [Member]

Note amount

$ 2,050,000

Debt Maturity Date

Feb. 22, 2028

Issuance of warrants | shares

512,500

Exercise price of warrants | $ / shares

$ 0.05

Debt conversion price | $ / shares

$ 0.05

Interest Expense

10,707

HealthCor Eighth Amendment Purchase Agreement [Member] | New Investors [Member]

Number of shares the note may be converted into | Number

50,000,000

HealthCor Ninth Amendment Purchase Agreement [Member]

Debt Maturity Date

Mar. 31, 2025

Issuance of warrants | shares

1,000,000

Exercise price of warrants | $ / shares

$ 0.53

Minimum cash balance required under existing loan documents

$ 5,000,000

Debt discount

378,000

Interest Expense

$ 43,352

43,352

Senior secured convertible notes, net of debt discount and debt costs

$ 69,638,663

69,638,663

HealthCor Ninth Amendment Purchase Agreement [Member] | Lower Range [Member]

Minimum cash balance required under existing loan documents

$ 2,000,000

HealthCor Fifth Amendment Purchase Agreement [Member]

Note amount

$ 6,000,000

Debt Maturity Date

Feb. 16, 2025

Issuance of warrants | shares

3,692,308

Exercise price of warrants | $ / shares

$ 0.52

Debt conversion price | $ / shares

$ 0.52

Debt discount

$ 1,093,105

Interest Expense

$ 25,443

21,456

HealthCor Fifth Amendment Purchase Agreement [Member] | New Investors [Member]

Number of shares the note may be converted into | Number

17,000,000

HealthCor Fifth Amendment Purchase Agreement [Member] | HealthCor Partners Fund [Member]

Number of shares the note may be converted into | Number

3,000,000

HealthCor Fourth Amendment Purchase Agreement [Member] | 2014 Senior Secured Convertible Note#1 [Member]

Note amount

$ 2,329,000

Minimum cash balance required under existing loan documents

5,000,000

HealthCor Fourth Amendment Purchase Agreement [Member] | 2014 Senior Secured Convertible Note#2 [Member]

Note amount

$ 2,671,000

HealthCor Fourth Amendment Purchase Agreement [Member] | 2014 Senior Secured Convertible Notes [Member]

Issuance of warrants | shares

4,000,000

Exercise price of warrants | $ / shares

$ 0.40

Number of shares the note may be converted into | Number

25,000,000

HealthCor Purchase Agreement [Member]

Interest Expense

$ 3,289,639

$ 2,746,081

HealthCor Third Amendment Purchase Agreement [Member]

Minimum cash balance required under existing loan documents

$ 5,000,000

HealthCor Third Amendment Purchase Agreement [Member] | Lower Range [Member]

Minimum cash balance required under existing loan documents

4,000,000

HealthCor Third Amendment Purchase Agreement [Member] | Upper Range [Member]

Minimum cash balance required under existing loan documents

$ 5,000,000

HealthCor Tenth Amedment Purchase Agreement [Member] | Common Stock [Member] | 2018 Investor [Member]

Issuance of warrants | shares

23,000,000

JOINT VENTURE AGREEMENT (Detail

JOINT VENTURE AGREEMENT (Details Narrative) - USD ($)	Feb. 02, 2018	Jan. 31, 2017	Dec. 31, 2015	Sep. 30, 2019	Feb. 23, 2018
Exercise price of warrants					$ 0.05
Joint Venture - Rockwell [Member]
Total cost to acquire remaining interest in joint venture		$ 1,213,786
Promissory note issued to acquire interest in joint venture		1,113,786
Cash payment to acquire remaining interest in joint venture		100,000		$ 461,287
Balloon payment to be paid		13,786
Debt outstanding				$ 363,786
Joint Venture - Rockwell [Member] | Warrant [Member]
Warrants issued for financing costs, warrants			1,151,206
Fair value of warrants issued to Rockwell for providing funding			$ 1,124,728
Fair value adjustment of warrants		$ 11,512
Joint Venture - Rockwell [Member] | PDL Modification Agreement [Member]
Cash payment to acquire remaining interest in joint venture	$ 50,000
Increase fair value of warrant	$ 13,814
Joint Venture - Rockwell [Member] | PDL Modification Agreement [Member] | Lower Range [Member]
Exercise price of warrants	$ 0.05
Joint Venture - Rockwell [Member] | PDL Modification Agreement [Member] | Upper Range [Member]
Exercise price of warrants	$ 0.52